NL-OMON47178已完成不适用
Anakinra versus treatment as usual in the treatment of acute gout - ATTACG
niversiteit Twente (prof. dr. M.A.F.J. van de Laar)0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* At least 18 years of age
- •* Signed written informed consent
- •* Identification of intracellular monosodium urate crystals in primary joint through aspiration of joint
排除标准
- •* Absolute contra-indication for all available types of urate lowering therapy (allopurinol, febuxostat and benzbromaron)
- •Contra-indications allopurinol: Hypersensitivity to the active substance or to any of the excipients (see for the excipients the official SPC for the brand given).
- •Contra-indications febuxostat: Hypersensitivity to the active substance or to any of the excipients (see for the excipients the official SPC for the brand given).
- •Contra-indications benzbromaron: Hypersensitivity to the active substance or to any of the excipients (see for the excipients the official SPC for the brand given). Patients with known liver disease. Concomitant use of hepatotoxic drugs, particularly antituberculosis agents. Hepatic porphyia. Severe renal impairment (clearance < 30 ml/min.). Patients with secretion of urate higher than 700 mg/24 hours (= 4.2 mmol/24 hour).Urolithiasis. Acute gout flare. ;* Absolute contra-indication for anakinra
- •Contra-indications anakinra: Hypersensitivity to the active substance or to any of the excipients (citric acid anhydrous, sodium chloride, disodium edetate dihydrate, polysorbate 80, sodium hydroxide, water for injections) or to E. coli derived proteins. Kineret must not be used in patients with severe renal impairment (creatinine clearance rate < 30 ml/minute). Kineret treatment must not be initiated in patients with neutropenia (absolute neutrophil count <1.5 x 109 /l). ;* Presence of liver disease that according to the treating physician precludes participation in the study;* Absolute contra-indication for all three possible standard of care treatments (colchicine, naproxen, prednisolon)
- •Contra-indications colchicine: Hypersensitivity to the active substance or to any of the excipients (microcrystalline cellulose (E460), lactose, sodium carboxy starch, magnesium stearate (E470b)). Women of childbearing age, unless effective contraceptive measures are taken. Colchicine should not be used in patients with severe renal impairment or severe hepatic impairment.
- •Contra-indications naproxen: Hypersensitivity to the active substance or to any of the excipients (potato starch, lactose, hydroxypropyl cellulose (200 CP), magnesium stearate, colloidal anhydrous silicon dioxide). Naproxen is contra-indicatied in patients who have previously shown allergic reactions (e.g. asthma, rhinitis or urticaria) in response to acetylsalicylic acid or other prostaglandin-synthesis inhibitors. Severe anaphylactoid reactions have been reported in these patients. In principle, naproxen must not be administered to patients with gastrointestinal ulcerations, congestive gastritis or atrophic gastritis, gastrointestinal bleeding or other bleeding such as cerebrovascular bleeding. Severe renal impairment.
- •Contra-indications prednisolon: Hypersensitivity to the active substance or to any of the excipients (lactose, magnesium stearate (E470b), silicon dioxide (E551), potato starch, pregelatinized potato starch, sodium (potato) starch glycolate, magnesium stearate (E572), erythrosine (E127)). Gastric and duodenal ulcers. Acute infectious processes, particularly viral infections and systemic fungal infections. Tropical worm infections. Administration after vaccination with a live attenuated virus. Ocular herpes simplex.;* Known history of allergy or sensitivity to latex;* Current use of any ULT (ULT therapies are allopurinol, febuxostat and benzbromaron);* Concurrent use of other IL-1 agents (to this categor
研究者
相似试验
进行中（未招募）
1 期
Anakinra versus treatment as usual in the treatment of acute goutGoutEUCTR2015-000696-27-NLprof. dr. M.A.F.J. van de Laar200
招募中
不适用
Anakinra versus treatment as usual in the treatment of acute gout // Anakinra versus standaardbehandeling bij acute jichtacute gout, anakinra, interleukin-1, pain, acute jicht, pijn, urate-lowering therapyNL-OMON28223prof. dr. M.A.F.J. van de Laar200
进行中（未招募）
1 期
Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroidsInflammation in periarticular structures in patients refractory to NSAIDs and / or corticosteroids.EUCTR2013-005402-65-ESInstitut de Recerca HSCSP20
进行中（未招募）
不适用
Treatment with Anakinra in TRAPS - NDMedDRA version: 9.1Level: LLTClassification code 10016202Term: Familial amyloidosisTRAPSEUCTR2006-001927-20-ITISTITUTO GIANNINA GASLINI
进行中（未招募）
不适用
Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritisEUCTR2005-004008-36-ITISTITUTO GIANNINA GASLINI